Prediabetes Not Associated With Higher Mortality in Patients Who Have Had PCI

There is no increased risk of mortality following percutaneous coronary intervention in patients with prediabetes.

Prediabetes is not associated with increased mortality in patients who have received percutaneous coronary intervention (PCI), according to study results presented at the National Lipid Association (NLA) Scientific Sessions 2023, held in Atlanta, Georgia, between June 1 and June 4, 2023.

Researchers used data from the National Inpatient Database of 2020 to identify prediabetic patients who had PCI. Outcomes included in-hospital mortality, acute kidney injury, cardiogenic shock, cerebrovascular accident (CVA), coronary artery thrombosis, intraoperative and postoperative complications, hospital length of stay, and total hospital charges.

A total of 432,765 patients received PCI, of whom 3% were prediabetic. Outcomes were compared in 11,515 prediabetic patients and 239,395 nondiabetic patients. The patients with prediabetes were younger (mean age, 63 years [95% CI, 63-64] vs 65 years [95% CI, 65-66]).

The patients with prediabetes had a lower rate of in-hospital mortality (n=145) compared with nondiabetic patients (n=7659; P <.0001), which was statistically significant.

Prediabetic patients also had a lower rate of acute kidney injury (P =.0207), cardiogenic shock (P =.0001), ventricular fibrillation (P =.0378), length of hospital stay (3.1 days [95% CI, 3.0-3.2] vs 4 days [95% CI, 3.5-4.0]), and total hospital charges ($114,222.8 [95 % CI, $109,026.4-$119,414.3] vs $125,877.7 [95% CI, $122,393.2-$129,363.2]).

No difference was observed in the 2 groups regarding coronary artery thrombosis (P =.1834), CVA (P =.5974), intraoperative and postoperative complications (P =.1071), and ventricular tachycardia (P =.6320).

“More research is needed to identify factors that increase mortality in patients who undergo PCI,” wrote the researchers.


Amoah JK, Noureldin S, Fatuyi M, Dekowski S, Cano FS. The outcome of percutaneous coronary intervention in prediabetic patients. A nationwide analysis. Abstract presented at: National Lipid Association (NLA) Scientific Sessions 2023; June 1-4, 2023; Atlanta, GA. Abstract #193